Priority Therapeutic Areas
A deep understanding of the needs of our patients and partners, and the development and manufacture of products to meet these needs is our goal. Over the past three decades, our company has evolved from a manufacturer of Active Pharmaceutical Ingredients to an international pharmaceutical company with a presence in more than 20 countries around the world, with the patient at the forefront. We have successfully developed and brought to market a wide range of products, many of which are leaders in their INNs.
Here are some of the most significant clinical areas in which we operate:
Oncology
Cancer is a disease that requires specialized treatment and care at each stage. By deeply studying the needs of patients and partners, we have developed a wide range of high-quality oncological medicines. The drugs we offer from the entire spectrum of cytotoxic, targeted and maintenance therapies allow you to effectively deal with cancer and the side effects associated with the therapy.
Oncology is also an area where we have successfully demonstrated our advanced research capabilities. Our many accomplishments include the development of the world's first recombinant human granulocyte colony stimulating factor (G-CSF) biosimilar, the world's first therapeutic monoclonal antibody biosimilar, and the unique pegfilgrastim analogue.
Gastroenterology
Heartburn is one of the common symptoms of gastroesophageal reflux disease, an increasingly common gastrointestinal disease worldwide.
To treat this widespread and debilitating ailment, Dr. Reddy's has developed a large number of drugs that reduce the acidity of gastric juice. In addition, the company offers a variety of products for the treatment of many other gastrointestinal diseases, such as irritable bowel syndrome, diarrhea, constipation - for both adults and children. We recently decided to enter the Hepatitis B and C segment of Hepatology Medicines to enable more people to get the medicines they need at affordable prices.
Cardiovascular diseases
Lifestyle and dietary changes are causing an unprecedented rise in cardiovascular disease. Probably the most common of these is arterial hypertension. After examining the changing needs of patients, Dr. Reddy's has developed a broad and diverse portfolio of antihypertensive drugs to help millions of people with hypertension. Our portfolio includes a number of successful drugs, including amlodipine, the combination of amlodipine with atenolol, a number of ACE inhibitors such as enalapril, and angiotensin receptor blockers (ARBs) such as telmisartan.
Because adherence to treatment is key to managing hypertension, our development efforts are focused on improving ease of use. This has led us, for example, to innovative solutions such as monthly packaging of Atorvastatin and Telmisartan in India.
Diabetes treatment
Like hypertension, diabetes is another rapidly spreading disease. In its portfolio, Dr. Reddy's has a variety of well established products such as metrofomin, plimepiride, glicazide and combinations to help diabetics maintain their health.
Many of our developments are focused on initiatives that would help patients better control their disease. For example, we have successfully developed a convenient form and dosage of metroformin that is easy to swallow and helps patients adhere to their prescribed treatment regimen.